A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)

Category Primary study
JournalANNALS OF HEMATOLOGY
Year 2002
This article has no abstract
Epistemonikos ID: 513beb5589d8c21a163c4a0243195c5d235035b3
First added on: Jun 22, 2013